Top Gum Industries Ltd.

Investor Presentation • Nov 24, 2024

The information included under this presentation (the "Presentation") is for informational purposes only and does not constitute or form any part of any offer to purchase securities and/or an invitation to make offers for their purchase or solicitation of any of the above regarding any securities of Top Gum Industries Ltd. (the "Company") and should not be regarded as a recommendation or an opinion. Any such offer or sale will be made on the basis of a prospectus published by the Company after receiving a permit from the Securities Authority and approval from the Tel Aviv Stock Exchange (hereinafter, respectively: "Securities Authority" and "the Stock Exchange").

This presentation does not purport to encompass or contain any information that may be relevant for the purpose of making any decision regarding an investment in the Company's securities and generally. This presentation does not replace independent data collection and analysis, it should be bear in mind that past data does not necessarily indicate future performance. The presentation includes data and statistics and other publications published by third parties, the content of which has not been independently verified by the Company. The presentation was made, for a convenient and concise presentation, and it does not exhaust the full data about the company and its activities and does

not replace the need to perform a full due diligence. The information contained in this presentation is incomplete and all that is stated in it is subject to a full due diligence and is not a substitute for reviewing reports published by the Company to the public and especially in the draft prospectus or final company prospectus, supplementary prospectus and shelf prospectus. The information under this Presentation is not a substitute for public Information and in the event of any conflict between the content of this presentation and the content of any public Information, the content of the Public Information shall prevail. The information in this Presentation should not be relied upon as any representation or warranty, express or implied, of the Company. No reliance should be made on the fairness, accuracy, completeness or correctness of the information or opinions contained herein. No legally binding obligations may be created, implied, or inferred from this Presentation. Various statements in this presentation include information which derives from forecasts, estimates, assessments, and other information pertaining to future events and/or matters, the materialization of which is uncertain and beyond the Company's control, and which constitute "forwardlooking information", as defined under the Israeli Securities Law, 1968. Forward-looking statements include descriptions regarding the intent,

belief, or current expectations of the Company and are not guaranteeing future results, performance, or achievements and are based on current expectations, estimations, and assumptions, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performances, or achievements of the Company may differ materially from what is or may be expressed or implied in this presentation due to a variety of factors, many of which are beyond the Company's control, including, without limitation, certain risk factors. The Company does not undertake any obligation to update or revise any of the forward-looking statements, whether as a result of new information, future events, or otherwise. Certain information and factual statements (including relating to markets or trends) contained herein are based on or derived from publicly available documents or independent third-party sources, and therefore the accuracy of such information and the assumptions on which such information is based has not been independently verified. Nothing in this presentation constitutes tax or business advice and does not constitute a substitute consulting appropriate advisors in these aspects. Every potential investor should seek advice and guidance in connection with potential investments, including tax advice is given such investor tax status.

Q3 2024 HIGHLIGHTS

• All-time record Q3
• · Revenue: 14.9\$ million, a 32% increase vs. Q3 23
• · Accelerated supplements sales growth of 42% vs. Q3 23
• · Adjusted EBITDA: \$2.3 million, a 60% increase
• Supplements backlog of 19.0\$
• · Tier-1 customer sales continues to grow
• Clal Insurance Enterprises Holdings Ltd. became an interested party holding 6.48%

•

The VMS Market

FUTURE GROWTH DRIVEN BY YOUNGER GENERATIONS WHO SEE GUMMIES AS THE PREFERRED DELIVERY FORMAT

All generations except for Boomers have a slight-to-major preference towards gummies

Which is your preferred dietary supplement format?

Gummies are the gateway for supplement usage

lopGum

Source: Nutrition Journal consumer survey U.S. consumer who frequently take dietary supplements. This survey launched in April 2023 via the Suzy online platform Question: "Please select your agreement with the following statements". N = 1,1066

How did we do?

IN-HOUSE PACKAGING AS A TOOL TO DRIVE ONE-STOP-SHOP CUSTOMIZED SOLUTIONS Bottle sales

(USD M, 22-24 Direct Growth)

~33% of end-product price is bottling & labeling

Maximum customization, shape, size, color, material, caps, seals, labels.

• One stop shop from production to final product, we deliver full value to our customers
• · In March 2022, a new bottling line became operational
• · In the US we are currently subcontracting our bottling to a 3rd party

INNOVATIVE DELIVERY SYSTEM Highest standards of nutraceuticals in the industry

GUMMICEUTICALS™ Truly sugar-free/No-added sugar | Prebiotic effect Organic (fiber or sugar based) | Unique fibers matrix

Organoleptic Experience

Flavor | Color | Texture | Odor | Shape High-resistance melting point Clean label ingredients

High Dosage

Highest dosage per one gummy without affecting the flavor Awarded winning products

Improved Functionality

Micro-encapsulation Masks flavors | Slow-release | Improves stability | Targeted release Enables new active ingredients | Preserves potency

8

|

A WIDE RANGE OF PROPRIETARY INNOVATIONS AND CATALOG PRODUCTS

ORGANIC GUMMIE

Unique Matrix Organic Gummies

Crafted with a proprietary fiber-organic matrix, our organic sugar-free gummy line is customizable to a wide range of formulas

The All-in-One Synbiotic Gummy

A proprietary combination of our dietary-fiber based gummy matrix coupled with high-dose probiotics in a combination of colors and flavors

MULTIMINERAL

The Building Blocks of Health

The optimal dosage and combination of magnesium, calcium, and zinc in a delightful cube form

cummicano

A Delicious Energy Shot

TopCapsTM microencapsulation high-dose caffeine, in a variety of delicious coffee flavors (and more!)

TITLE IN

High-Dose Iron, No Metallic Taste

Utilizing our proprietary TopCapsTM technology, the ultimate combination of high-dosage iron with prebiotic fibers, delivers a nutritious, great-tasting gummy

1,000 mg of Natural Liquid Honey

With a high-dosage of liquid honey, the gummies' unique hexagonal shape are more than supplements - they're treats.

INCREASING CAPACITY TO MEET GROWING DEMAND

• Test runs of the first production line are expected to commence by the end of the year / during Q1 2025
• · The company continuous to explore options for the purchase or establishment of a manufacturing, bottling and logistics center in North America:
  • · In-house bottling for North America
  • Made in the USA .
  • Proximity to the main customers

USD thousands

						YoY
	Q3 2024	Q3 2023	Change	YTD 2024	YTD 2023	Change
Revenue	14,884	11,259	32%	44,636	37,208	20%
Cost of sales	9,810	7,721	27%	29,124	24,468	19%
Gross profit	5,074	3,538	43%	15,512	12,740	22%
R&D	1,007	977	3%	2,490	2,472	1%
S&M	1,399	865	62%	3,694	3,104	19%
G&A	1,963	1,008	95%	5,659	4,016	41%
Operating profits	705	688	2%	3,669	3,148	17%
Finance expenses	81	230	-65%	9	468	-08%
Profit before tax	624	459	36%	3,660	2,681	37%
'l'ax expenses	137	113	21%	638	519	23%
Net profits	487	346	41%	3,022	2,162	40%
EBITDA	1,258	1,228	2%	5,386	4,663	16%
Adjusted Ebitda	2,267	1,417	60%	7,260	5,748	26%
	15.2%	12.6%		16.3%	15.4%

Non-GAAP EBITDA excludes one-time expenses from ESOP grants and bonuses to employees regarding IPO / Equity transactions

SOLID FINANCIAL STRENGTH

USD thousands

	09-24	09-2
Assets
Current asset	52,282	38,257
Non-current assets	66,491	52,148
Total asset	118,773	90,405
Liabilities and equity
Current liabillities	25,147	29,305
Non-current liabillities	23,071	15,800
Equity	70,555	45,300
Total liabillities and equity	118,773	90,405

Thank you